Obesity Treatment News
Source-linked news on obesity medications and weight-loss surgery.
Search the news archive
Explore: Insurance · Safety · Revision surgery
Top story
-
Peers of high‑volume robotic bariatric adopters had 70% lower odds of adopting the robot themselves
A Michigan Collaborative study of 87,068 operations found peers of busy early robotic adopters had adjusted odds of 0.30 for starting robotics. Concentrated use may limit colleagues' console time and supervised cases.
More to know
-
Tirzepatide needs backup contraception for four weeks after starts and dose increases, review says
A 2026 Clinics review says tirzepatide starts and dose increases can lower how much of the pill the body sees. The authors support four weeks of backup contraception in those windows. Better periods or labs are not proof of better live-birth outcomes.
-
Medicare fee‑for‑service bariatric surgery rates fell from 47.1 to 16.6 per 100,000 between 2014 and 2024
A JAMA Surgery research letter used an interrupted time series on public Medicare data. Rates were already declining before COVID-19, dropped in 2020, and fell faster after 2022 as GLP-1 use rose, without proving that medicines replaced operations.
Latest briefs
What changed and why it matters.
-
FDA warns against using the chin‑fat injection Kybella elsewhere on the body, citing 129 adverse event reports
A Drug Safety Communication issued September 15, 2026 adds labeling warnings to deoxycholic acid injection. FDA counted 129 adverse event cases from use outside the approved area under the chin, including vision and nerve injury, plus 117 cases of nodules or masses unresolved for a mean of 143 days.
-
Prior GLP‑1 users had fewer 90‑day heart and kidney events after bariatric surgery, in a design that cannot show cause
A US medical records study matched 11,052 adults who filled a GLP-1 or tirzepatide prescription in the year before bariatric surgery against 11,052 who did not. Serious heart events occurred in 0.3% versus 0.6% over the first 90 days, and kidney events in 1.4% versus 2.3%.
-
No rise in suicidal thinking among 9,222 teenagers on GLP‑1 drugs, and the apparent benefit did not survive a second test
A TriNetX cohort matched 9,222 adolescents starting semaglutide, liraglutide or tirzepatide against 9,222 on lifestyle care and tracked psychiatric outcomes for up to three years. Rates were no higher in the treated group. Against metformin rather than lifestyle care, the apparent advantage disappeared.
-
High uric acid readings fell from 57% of patients to 2% two years after gastric bypass, in a 94‑person series
A single center tracked serum uric acid in 94 adults through 24 months after Roux-en-Y gastric bypass. Mean levels dropped from 7.34 to 4.71 mg/dL, and 96% of those who started with a high reading ended in the normal range. There was no comparison group, and the study did not count gout attacks.
-
A 45‑member expert panel urges eating disorder screening before every GLP‑1 prescription, on evidence it calls limited
World Psychiatry published consensus recommendations on 15 September 2026. The panel reached 100% agreement that GLP-1 medicines should generally be avoided in active eating disorders, and 94.7% that every patient should be screened first. The authors stress this is expert opinion, not trial evidence.
-
European obesity society says GLP‑1 drugs have outrun the care systems meant to deliver them
The European Association for the Study of Obesity argued on 3 September 2026 that the medicines have advanced faster than the staffing, monitoring and funding needed to use them well. It is a position statement, not a guideline or new data, and half its authors report drugmaker payments.
-
Michigan man gets 21 months for selling Chinese semaglutide and tirzepatide as research chemicals
Federal prosecutors say the products were imported from China, sold without prescriptions under a research-only label, and some were marked as a product of the USA. They also omitted the boxed warning that keeps these drugs away from people with a family history of thyroid cancer.
-
Obesity Medicine Association's 2026 heart statement urges treating obesity first, and says it is not a guideline
The statement gathers trial evidence that semaglutide cut major cardiac events by 20% and that gastric bypass and sleeve gastrectomy lower long-term heart attack, stroke and death risk. It carries no graded recommendations, and its authors disclose extensive ties to obesity drug manufacturers.
-
Sleeve surgery ranked first among six obesity treatments, on evidence the authors graded very low certainty
Sleeve gastrectomy beat the endoscopic version by 11.3 percentage points of body weight at 12 months. All 17 studies behind the ranking were non-randomized, and the serious complication comparison came out inconclusive rather than favorable to the endoscopic procedure.
-
Suicide‑related events made up under 0.3% of 42,941 European GLP‑1 safety reports, a count that cannot show cause
Reports naming semaglutide or liraglutide mentioned these events about 2.5 to 2.7 times as often as reports naming tirzepatide, but voluntary reports cannot measure risk, and the FDA asked drugmakers to drop the suicidality warning in January 2026 after pooling 91 trials.
-
Newer bariatric surgery criteria flagged 2.8 times as many adults as the 1991 rules in 37 countries
An analysis of World Health Organization survey data put 48.5 million adults over the 2022 ASMBS and IFSO evaluation threshold by 2030, against 17.1 million under the 1991 NIH criteria. The United States was not among the countries studied.
-
GLP‑1 drugs after bariatric surgery produced about 9% weight loss at one year, on weak pooled evidence
A review of 27 studies found roughly 9% total weight loss at 12 months with liraglutide or semaglutide in people who had already had surgery. The confidence range for liraglutide ran from 0.83% to 17.60%.
-
Diabetes stayed in remission for 81% of 221 sleeve patients in a Shanghai series, with three tests predicting who
Surgeons at Huashan Hospital followed patients for an average of 3.6 years after sleeve gastrectomy and built a three-item score from how much diabetes medication a patient took beforehand and how much insulin the pancreas could still produce.
-
Depression scores fell and suicide screening did not worsen in a 44‑teenager GLP‑1 chart review
A Wisconsin clinic looked back at 44 patients aged 12 to 21 treated with liraglutide or semaglutide. Depression scores dropped in the 15 who had questionnaires at two visits, and none of the 23 screened twice for suicide risk got worse.
-
Gastric bypass beat sleeve on every six‑month outcome in a 116,195‑patient registry comparison
A 2023 MBSAQIP analysis matched patients across four weight-loss operations. Bypass led sleeve on weight and every condition reported, and the duodenal switch led the field, on far fewer patients and only six months of follow-up.
-
Sleeve patients on SSRIs lost less weight in a 68‑person matched study, with depression itself not ruled out
A single-center review of 799 bariatric patients found lower 12-month weight loss among sleeve gastrectomy patients taking an SSRI. Gastric bypass patients showed no difference, and the comparison group had no depression or anxiety at all, so the medicine and the condition cannot be told apart.
-
Large GLP‑1 review finds no bone or joint harm, and a lean mass drop the authors call low certainty
A World Health Organization commissioned analysis of 60 studies and more than 1.2 million people found no measurable effect on bone density, fracture risk or knee arthritis symptoms. It did find less lean body mass, but rated that evidence low certainty and tied it mostly to weight loss itself.
-
Judge lets part of Lilly’s Mochi lawsuit proceed, while dismissing an advertising conspiracy theory
The September 8 order preserves Lilly’s civil-conspiracy theory against Aequita concerning an alleged violation of California’s unfair-competition law. It does not establish wrongdoing or change patient access.
-
Weight loss largely held at seven years after one‑anastomosis gastric bypass in an 80‑patient series
An Israeli single-center review of 80 patients operated on in 2016 reported average excess weight loss of 74.6 percent at seven years, with quality of life improved and major 30-day complications in 5.1 percent.
-
UK doctors' union tells GPs not to start Wegovy for heart risk without written proof of funding
NICE approved semaglutide for cardiovascular risk reduction in England on 7 May with a 90 day funding deadline. In September the BMA told practices to get written confirmation of commissioning before prescribing.
-
Serious heart and stroke events followed 0.12% of bariatric surgeries, concentrated in advanced organ disease
A registry analysis of 1,095,255 US operations found 1,368 major heart or stroke events within 30 days. Dialysis, a prior heart attack, a prior lung clot, insulin-treated diabetes and a longer blood pressure drug list marked the highest risk.
-
Sleeve surgery beat the endoscopic version on weight loss, while the endoscopic version had fewer complications
A meta-analysis of ten studies covering 7,442 patients found laparoscopic sleeve gastrectomy produced 8 to 13 percentage points more total body weight loss than endoscopic sleeve gastroplasty out to two years. The endoscopic procedure had roughly half the adverse events and a third the rate of new reflux.
About this publication
Reporting standards and transparency
How we report
Obesity Treatment News is a BariatricPal publication. We review the linked source material, explain what changed, and state what the evidence does not establish.
Corrections
Send factual corrections through Contact BariatricPal. Material corrections are dated and noted in the article.
Ownership and commerce
BariatricPal owns OTN and the BariatricPal Store. Pages may include clearly separated advertising or store links. Commerce does not change the source summary.
About BariatricPal · Brief author · Contact · Weight-loss medications · Weight-loss surgery